Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MiNK Therapeutics (INKT)
NASDAQ:INKT
Holding INKT?
Track your performance easily
Earnings Data
Report Date
Mar 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.05Last Year’s EPS
-$0.16Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: -34.01%
|Next Earnings Date:Mar 19, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with significant advancements in clinical trials, efficient cost management, and promising data presentations at SITC. However, concerns about the cash position and early stages of the GVHD program indicate areas that require attention.Company Guidance
During the MiNK Therapeutics Q3 2024 earnings call, the company highlighted significant advancements and strategic initiatives, focusing on its iNKT cell therapy platform. Key metrics discussed included a nearly 60% reduction in operating burn from the previous year, achieved through external funding and manufacturing efficiencies. The financials revealed a cash balance of $6.3 million at the end of the quarter, with a net loss of $1.8 million for the three months ending September 2024, compared to $5.1 million for the same period in 2023. The company is progressing with its Phase II trial for advanced gastric cancer, with enrollment expected to complete by mid-next year and plans for a data update in early 2025. Additionally, ongoing efforts in reducing the costs associated with manufacturing, along with strategic partnerships, are aimed at bolstering financial discipline and enhancing clinical outcomes.Operating Efficiency and Cost Reduction
MiNK Therapeutics achieved a 60% reduction in operating burn compared to the previous year, alongside improvements in manufacturing efficiencies that reduced cost of goods and increased production capacity.
Advancements in Clinical Programs
Progress in the Phase II trial for second-line advanced gastric cancer at Memorial Sloan-Kettering Cancer Center with promising efficacy signals. Additionally, advancements in the PRAME-TCR IND program were highlighted.
Strategic Leadership Addition
Dr. Robert Kadlec joined the Board of Directors, bringing expertise in public health and biodefense, expected to provide strategic value as MiNK expands its iNKT cell platform.
Positive Preclinical and Clinical Data
At the SITC meeting, data showed durable disease control with agenT-797 in heavily pretreated solid tumor patients, and its combination with bispecific engagers demonstrated increased tumor cell killing.
Financial Discipline
Significant reduction in cash used in operations to $3 million for Q3 2024 from $7.8 million in Q3 2023, with a net loss reduction to $1.8 million from $5.1 million year-over-year.
---
INKT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
INKT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $0.79 | $0.75 | -5.06% |
| Aug 13, 2024 | $0.84 | $0.85 | +1.19% |
| May 14, 2024 | $0.98 | $1.12 | +14.29% |
| Mar 21, 2024 | $0.90 | $0.89 | -1.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does MiNK Therapeutics (INKT) report earnings?
MiNK Therapeutics (INKT) is schdueled to report earning on Mar 19, 2025, TBA Not Confirmed.
What is MiNK Therapeutics (INKT) earnings time?
MiNK Therapeutics (INKT) earnings time is at Mar 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INKT EPS forecast?
INKT EPS forecast for the fiscal quarter 2024 (Q4) is -$0.05.
---